版權(quán)說明:本文檔由用戶提供并上傳,收益歸屬內(nèi)容提供方,若內(nèi)容存在侵權(quán),請進(jìn)行舉報或認(rèn)領(lǐng)
文檔簡介
GastricCancerEpidemiologyJemalA,BrayF,CenterMM,etal.Globalcancerstatistics.CACancerJClin2011;61:69.EpidemiologyJemalA,BrayF,CenterMM,etal.Globalcancerstatistics.CACancerJClin2011;61:69.RiskFactors1.NutritionLowfatorproteinconsumptionSaltedmeatorfishHighnitrateconsumptionHighcomplex-carbohydrateconsumption2.Environment
Poorfoodpreparation(smoked,salted)LackofrefrigerationPoordrinkingwater(wellwater)Smoking3.SocialLowsocioeconomicstatus(exceptinJapan)RiskFactors4.MedicalPriorgastricsurgery
HelicobacterpyloriinfectionGastricatrophyandgastritis
AdenomatouspolypsPerniciousanemiaMalegenderEtiologicalFactors(RiskFactors)Pathology1.Earlygastriccancer(EGC)Gastriccancerconfinedtothemucosaorsubmucosa,regardlessofthepresenceorabsenceoflymphnodemetastasis2.Advancedgastriccancer(AGC)
Cancercellsinfiltratetheproprialmusclelayerorserosa
EGCPathologyI:protrudedIIa:superficiallyelevatedIIc:superficiallydepressedIIb:superficiallyflatIII:excavatedEGC:EndoscopicimagesTypeITypeIITypeIIIPathologyBorrmann's
classificationofgastriccancerbasedongrossappearanceAGC:Borrmann’sclassificationLinitisplasticaTstagearedefinedbydepthofpenetrationintothegastricwallLaminapropriaT1aT1bT4aT4bT3SubserosalconnectivetissueT1bT1aT4aT4bTstageGroupingofRegionalLymphNodes(Groups1-3)byLocationofPrimaryTumorAccordingtotheJapaneseClassificationofGastricCarcinomaNstage
MetastesisDirectinvasionLyphmaticmetastesisHematogenousmetastasisSeedingmetastasisClinicalPresentation1.Vagueepigastricdiscomfort2.Epigastricpain3.Weightloss,
anorexia,fatigue,orvomiting4.Hematemesis,anemicPhysicalsigns1.Apalpableabdominalmass2.Apalpablesupraclavicularlymphnode3.Apalpablemassbyrectalexamination4.Apalpableovarianmass(Krukenberg'stumor)ExaminationEndoscopyM-SCT(multipledetector-rowspiralCT)MRIBUS&EUSDouble-contrastradiographyDL(diagnosticlaparoscopy)PET-CTClinicpathologicalStagingEUSLaprascopyBUSCTPET-CTCTisthemainlyprocedureMRIEndoscopyCarcinomainsituAdvancedcarcinomaNicheDouble-ContrastBariumUpperGIRadiographyEUSEUSTTNCTscanABCTNM1T4N2M1CTscanMRIPET-CT:T3N2BUSLivermetastasisKrukenberg’stumorleftrightTTLaparoscopyAbdominalmetastasisTreatmentforGastricCancerSurgeryEndoscopicmucosalresection(EMR)Endoscopicsubmucosaldissection(ESD)LaparoscopicSurgeryOpenSurgeryChemotherapyChemoradiotherapyTargettherapyEMRforEarliergastriccancer(EGC)CriteriaforEMRNCCN2013V2:1.TisorT1a2.Well
ormoderatelydifferentiatedhistology3.Tumorslessthan15mminsize,4.AbsenceofulcerationandnoevidenceofinvasivefindingCriteriaforEMRAbsoluteindication(EMR/ESD):DifferentiatedadenocarcinomaT1adiameteris≤2cmwithoutulcerfinding(UL-)JapaneseGastricCancerAssociationExpandedindication(ESD):TumorsclinicallydiagnosedasT1aand:(a)Differentiated,UL(-),but
>2cm(b)Differentiated-type,UL(+),and≤3cm(c)Undifferentiated-type,UL(-),and≤2cmEMREMREMR1.Difficulttoresectlargethan20mmtumorinsize2.DifficulttoresectulcerativelesionsLimitationofEMRtechniquesESDwasdevelopedESDforEarliergastriccancer(EGC)ESDOitaDigestiveOrgansHospital
ESDOitaDigestiveOrgansHospital
Principlesofradicaloperationforgastriccancer1.Negativemargin(R0resection,adequatemargins≥4cm)2.D2lymphnodedissectionforadvancegastriccancer3.Subtotalgastrectomyfordistalgastriccancer4.TotalorproximalgastrectomyforproixmalgastriccancerSurgicalTreatmentforGastricCancerLaparoscopicResection1.AsuitableprocedureforECG(Ourexperience)2.TheefficacyandsafetyofthisapproachforadvancgastriccarcinomarequiresfurtherinvestigationOpenSurgeryforAdvancedGastricCancer1.AsuitableprocedureforACG2.R0resection3.R1resection4.R2resectionPrinciplesofadvancedgastriccancersurgery
Gastrectomywithregionallymphatics:perigastriclymphnodes(D1)andthosealongthenamedvesselsoftheceliacaxis(D2),withagoalofexamining15orgreaterlymphnodesGastrectomywithD2lymphadenectomyisthestandardtreatment
forcurablegastriccancerineasternAsia
GastrectomyandD2lymphadenectomyforadvancedgastriccarcinomaGastrectomyLymphadenectomyRoux-en-YanastomosisBillrothIIanastomosisAnastomosisSubtotalgastrectomyTotalgastrectomyLeftgastricAHepaticASplenicANo.11LNPortalVeinSpleenStomachGreateromentumAdjuvantTherapyChemotherapyRadiationTherapyTargetedTherapyECF:Epirubicin,Cisplatin,5-FuFOLFOX:Oxaliplatin,5-Fu,CFSOX:S-1,OxaliplatinXELOX:Capecitabin,OxaliplatinDCF:Docetaxel,Cisplatin,5-Fu……ChemotherapyPreoperativeChemotherapy
PostoperativeChemotherapyUlcerativemassatantrumofstomach,about4*5cminsizeThelesionisabout2.0*1.0cminsizeAfter3coursesofFOLFOXBeforetheneoadjvantchemotherapyOurexperiencePreoperativechemotherapyAfter3coursesofpreoperative
chemotherapyPreoperativechemotherapyOurexperienceLymphadectomyofgroup7,8,9LiverafterChemotherapyOurexperiencefoamcellsinlaminapropria(40×10)OurexperienceTargetedTherapyHerccptin
Herb-2receptorinhibitorIressaEGFRinhibitorAvastin
VEGFRinhibitor
OtherMolecularMedicineInterventionsofGastricCancer1.Oncogeneactivationandtargetedtherapy2.Tumor-suppressor-geneinactivationandrelatedtherapy3.Apoptosistargetedtherapy4.Anti-metastasistherapy5.Telomeraseinhibitiontherapy6.Gene
溫馨提示
- 1. 本站所有資源如無特殊說明,都需要本地電腦安裝OFFICE2007和PDF閱讀器。圖紙軟件為CAD,CAXA,PROE,UG,SolidWorks等.壓縮文件請下載最新的WinRAR軟件解壓。
- 2. 本站的文檔不包含任何第三方提供的附件圖紙等,如果需要附件,請聯(lián)系上傳者。文件的所有權(quán)益歸上傳用戶所有。
- 3. 本站RAR壓縮包中若帶圖紙,網(wǎng)頁內(nèi)容里面會有圖紙預(yù)覽,若沒有圖紙預(yù)覽就沒有圖紙。
- 4. 未經(jīng)權(quán)益所有人同意不得將文件中的內(nèi)容挪作商業(yè)或盈利用途。
- 5. 人人文庫網(wǎng)僅提供信息存儲空間,僅對用戶上傳內(nèi)容的表現(xiàn)方式做保護處理,對用戶上傳分享的文檔內(nèi)容本身不做任何修改或編輯,并不能對任何下載內(nèi)容負(fù)責(zé)。
- 6. 下載文件中如有侵權(quán)或不適當(dāng)內(nèi)容,請與我們聯(lián)系,我們立即糾正。
- 7. 本站不保證下載資源的準(zhǔn)確性、安全性和完整性, 同時也不承擔(dān)用戶因使用這些下載資源對自己和他人造成任何形式的傷害或損失。
最新文檔
- 2024至2030年吸池頭項目投資價值分析報告
- 2024年環(huán)保安全規(guī)范:承包商合作協(xié)議版
- 財務(wù)管理制度說明與解讀
- 企業(yè)技術(shù)創(chuàng)新與合作支持協(xié)議
- 出版行業(yè)圖書銷售退貨政策
- 2024年耗材采購與服務(wù)協(xié)議
- 2024年抵押貸款購銷合同模板風(fēng)險預(yù)警系統(tǒng)3篇
- 2025年度個人土地承包經(jīng)營權(quán)繼承合同范本3篇
- 2025版高端礦泉水品牌代理銷售合同3篇
- 可再生能源消納保障機制合作協(xié)議
- 大唐電廠采購合同范例
- 國潮風(fēng)中國風(fēng)2025蛇年大吉蛇年模板
- 《信托知識培訓(xùn)》課件
- 物業(yè)項目經(jīng)理崗位競聘
- 第8課《蒲柳人家(節(jié)選)》教學(xué)設(shè)計-2023-2024學(xué)年統(tǒng)編版語文九年級下冊
- 幼兒沙池活動指導(dǎo)方法
- 2024年冬季校園清雪合同
- 翻譯美學(xué)理論
- 15J403-1-樓梯欄桿欄板(一)
- 中國傳統(tǒng)樂器蕭介紹
- 2024屆華中師范大學(xué)新高三第一次聯(lián)考試題
評論
0/150
提交評論